Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash & Equivalents (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Cash & Equivalents data on record, last reported at $21.6 million in Q2 2025.

  • For Q2 2025, Cash & Equivalents rose 35.7% year-over-year to $21.6 million; the TTM value through Jun 2025 reached $21.6 million, up 35.7%, while the annual FY2024 figure was $48.3 million, 34.44% up from the prior year.
  • Cash & Equivalents reached $21.6 million in Q2 2025 per SNTI's latest filing, down from $33.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $139.8 million in Q2 2022 and bottomed at $10.5 million in Q3 2024.
  • Average Cash & Equivalents over 5 years is $50.6 million, with a median of $38.1 million recorded in 2022.
  • Peak YoY movement for Cash & Equivalents: soared 68.55% in 2022, then plummeted 73.71% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $56.0 million in 2021, then grew by 2.83% to $57.6 million in 2022, then tumbled by 37.65% to $35.9 million in 2023, then soared by 34.44% to $48.3 million in 2024, then crashed by 55.33% to $21.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $21.6 million in Q2 2025, $33.8 million in Q1 2025, and $48.3 million in Q4 2024.